MOTS-c: The Mitochondrial Peptide Behind Exercise Benefits and Metabolic Health

MOTS-c is a 16-amino acid peptide encoded within mitochondrial DNA that activates AMPK, the same metabolic pathway triggered by exercise. Circulating levels drop by roughly 21% between young adulthood and old age, correlating with declining metabolic health. In animal studies, MOTS-c supplementation improves insulin sensitivity, increases running endurance, and reverses age-related muscle dysfunction. The FDA will review MOTS-c for the 503A compounding bulks list at its July 2026 PCAC meeting, signaling growing regulatory interest in this mitochondrial-derived peptide.

What Is MOTS-c?

MOTS-c stands for Mitochondrial Open Reading Frame of the 12S rRNA Type-c. Unlike most peptides that are encoded in nuclear DNA, MOTS-c is encoded directly within the mitochondrial genome, making it one of only a handful of known mitochondria-derived peptides (MDPs).

Dr. Pinchas Cohen and his team at the University of Southern California first identified MOTS-c in 2015. The peptide consists of 16 amino acids and is highly conserved across species, from mice to humans. This conservation suggests an ancient and fundamental role in metabolism.

MOTS-c is expressed in multiple tissues, with particularly high concentrations in skeletal muscle, heart, brain, and liver. What makes it unusual is its ability to act as a signaling molecule between mitochondria and the nucleus, a process called retrograde signaling. When cells experience metabolic stress, MOTS-c translocates from mitochondria into the nucleus, where it directly influences gene expression.

How Does MOTS-c Work? The AMPK Connection

The primary mechanism behind MOTS-c's effects involves AMP-activated protein kinase (AMPK), often called the "master metabolic regulator." AMPK acts as a cellular fuel gauge, activating energy-producing pathways when cellular energy runs low.

MOTS-c activates AMPK through an indirect pathway. It increases levels of AICAR (5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside), an intermediate in purine synthesis that is a known AMPK activator. Once AMPK is activated, several downstream effects occur:

Glucose uptake increases. AMPK activation upregulates GLUT4, the glucose transporter responsible for moving glucose into muscle and fat cells. A 2025 study in Frontiers in Physiology demonstrated that MOTS-c treatment restored GLUT4 expression and improved glucose metabolism in diabetic rat hearts.

Fat oxidation ramps up. Activated AMPK shifts cellular metabolism toward burning fatty acids for fuel rather than storing them.

Mitochondrial biogenesis accelerates. AMPK triggers the production of new mitochondria, improving overall cellular energy capacity.

mTOR activity decreases. Through AMPK activation, MOTS-c indirectly suppresses mTOR (mechanistic target of rapamycin), a pathway associated with cellular growth. Reduced mTOR activity promotes autophagy, the cellular cleanup process linked to longevity in multiple animal models.

Nuclear Translocation and Gene Regulation

Under normal conditions, MOTS-c remains primarily in the cytoplasm near mitochondria. But when cells face metabolic stress, such as exercise, nutrient deprivation, or oxidative damage, MOTS-c translocates into the nucleus.

Once in the nucleus, MOTS-c interacts with NRF2 (nuclear factor erythroid 2-related factor 2), a transcription factor that controls antioxidant and stress-response genes. This interaction enhances expression of genes that protect mitochondria and improve cellular resilience.

This nuclear translocation appears to be AMPK-dependent. When researchers block AMPK signaling, MOTS-c fails to enter the nucleus effectively, suggesting that AMPK activation is required for the full range of MOTS-c effects.

MOTS-c as an Exercise Mimetic

One of the most striking findings about MOTS-c is its connection to physical exercise. Research from the Cohen lab at USC, published in Nature Communications in 2021, demonstrated that MOTS-c levels rise significantly during and after exercise.

In muscle cells, MOTS-c levels increased nearly 12-fold after exercise and remained partially elevated four hours into recovery. Blood plasma levels rose by approximately 50% during exercise before returning to baseline during rest.

This connection led researchers to test whether MOTS-c could reproduce some benefits of exercise. The results were notable:

Running capacity doubled. Mice treated with MOTS-c ran nearly twice as far on treadmill tests compared to untreated controls. This improvement occurred across young, middle-aged, and old mice.

Balance and coordination improved. On rotarod tests measuring balance, MOTS-c-treated mice of all ages outperformed their untreated counterparts.

Weight gain slowed on high-fat diets. Even mice fed high-fat diets showed reduced weight gain after MOTS-c treatment, suggesting metabolic protection independent of exercise behavior.

It's worth noting that MOTS-c doesn't replicate all exercise benefits. Cardiovascular adaptations, neuromuscular coordination improvements, and social benefits of exercise won't come from a peptide. But the metabolic and mitochondrial pathways activated by MOTS-c overlap substantially with those triggered by physical activity.

Age-Related Decline: Why MOTS-c Levels Drop

Circulating MOTS-c levels decline with age, and this decline correlates with reduced metabolic efficiency. Human studies have quantified this drop:

Blood MOTS-c levels in young adults (18-30 years) are approximately 11% higher than in middle-aged adults (45-55 years) and 21% higher than in older adults (70-81 years).

Interestingly, while blood levels decline, skeletal muscle MOTS-c expression actually increases with age. A study published in the journal Aging found that older and middle-aged men had roughly 1.5-fold higher skeletal muscle MOTS-c expression compared to young men. This paradoxical finding suggests the body may be attempting to compensate for reduced circulating levels by producing more locally in muscle tissue.

The age-related decline in circulating MOTS-c tracks with several hallmarks of metabolic aging:

• Reduced insulin sensitivity
• Decreased exercise capacity
• Loss of muscle mass and function
• Impaired mitochondrial function

Whether low MOTS-c causes these changes, results from them, or both remains under investigation. But the correlation is strong enough that researchers view MOTS-c as both a potential biomarker of metabolic health and a therapeutic target.

The Longevity Connection

Perhaps the most intriguing observation comes from population genetics. An exceptionally long-lived Japanese population harbors a specific mitochondrial DNA variant (m.1382A>C) that produces a functional variant of MOTS-c. While this doesn't prove causation, it adds to evidence connecting MOTS-c to healthy aging.

In animal studies, late-life MOTS-c treatment (starting at roughly 70 human-equivalent years in mice) increased physical capacity and markers of healthspan. Treatment showed a trend toward increased median lifespan (6.4%) and maximum lifespan (7.0%), though these results didn't reach statistical significance in all measures.

MOTS-c and Type 2 Diabetes Research

The connection between MOTS-c and metabolic disease has received considerable research attention. Multiple studies have found that people with type 2 diabetes have lower circulating MOTS-c levels than healthy controls.

More specifically, those with worse glucose control (higher HbA1c levels) tend to have the lowest MOTS-c levels. Similar reductions appear in gestational diabetes, coronary endothelial dysfunction, and obese children and adolescents.

Recent research has explored whether MOTS-c supplementation could address these deficits:

Pancreatic islet protection. A 2025 study in Experimental & Molecular Medicine found that MOTS-c treatment reduced pancreatic islet cell senescence in both type 1 and type 2 diabetes mouse models. The researchers described MOTS-c as a potential "senotherapeutic" that helps insulin-producing cells stay functional longer.

Cardiac metabolism restoration. A 2025 Frontiers in Physiology study showed that MOTS-c treatment in diabetic rats improved cardiac mitochondrial function and AMPK signaling, addressing some of the metabolic defects that lead to diabetic heart disease.

Insulin sensitivity improvement. In old mice, just seven days of MOTS-c administration restored insulin sensitivity to levels comparable to young, healthy mice.

The mechanism appears straightforward: MOTS-c activates AMPK, which increases GLUT4 expression and glucose uptake into muscle cells. This bypasses some of the insulin signaling defects that characterize type 2 diabetes.

Muscle Protection and Anti-Atrophy Effects

Beyond metabolic benefits, MOTS-c shows promise for protecting against muscle wasting. Plasma MOTS-c levels are inversely correlated with myostatin levels in humans. Myostatin is a protein that inhibits muscle growth; higher myostatin means more muscle breakdown.

In laboratory studies, MOTS-c prevented muscle cell atrophy induced by palmitic acid (a saturated fatty acid linked to obesity-related muscle problems). The mechanism involves AKT phosphorylation, which inhibits FOXO1, a transcription factor that activates muscle-wasting genes.

A 2024 study in iScience revealed another mechanism: MOTS-c directly binds and activates casein kinase 2 (CK2), recruiting the chaperone protein HSP90AB1 into the CK2 complex. This modifies the protein-folding network in skeletal muscle, potentially preventing the protein misfolding associated with muscle dysfunction during aging.

Clinical Development: The CB4211 Story

CohBar, a biotechnology company founded with involvement from Dr. Pinchas Cohen, developed CB4211, an improved analog of MOTS-c. This became the first mitochondria-based therapy to enter clinical testing in humans.

The Phase 1a/1b trial (NCT03998514) enrolled 65 healthy adults in the Phase 1a portion and 20 obese subjects with nonalcoholic fatty liver disease (NAFLD) in Phase 1b. Results announced in August 2021 showed:

Safety: CB4211 was well-tolerated with no serious adverse events. The most common side effect was injection site reactions.

Liver enzyme reduction: Relative to placebo, ALT decreased by 25% and AST by 17%. These liver enzymes are markers of liver stress.

Glucose improvement: Blood glucose levels dropped by 6%.

Liver fat: Fat reduction measured by MRI was similar between treatment and placebo groups (roughly 5%), though 36% of CB4211 patients saw over 30% relative reduction in liver fat content.

Despite these promising signals, clinical development of CB4211 was discontinued. The challenges facing MOTS-c as a therapeutic include low bioavailability, poor stability, short half-life, and a tendency to persist at the injection site rather than distributing systemically. These are common problems for peptide drugs and represent the primary hurdles to clinical translation.

FDA Regulatory Status: July 2026 Review

MOTS-c's regulatory path has shifted substantially. After being placed in Category 2 (restricted from compounding) along with other peptides in late 2023, MOTS-c is now being reconsidered.

On April 15, 2026, the FDA announced it would remove MOTS-c from Category 2, along with BPC-157, TB-500, Epitalon, and several other peptides. However, removal from Category 2 doesn't automatically mean compounding pharmacies can produce it.

The Pharmacy Compounding Advisory Committee (PCAC) will meet July 23-24, 2026 to specifically discuss MOTS-c (both free base and acetate forms) for potential inclusion on the 503A Bulks List. The FDA is reviewing MOTS-c for obesity and osteoporosis applications.

If the PCAC recommends inclusion and the FDA completes formal rulemaking, licensed compounding pharmacies would be permitted to prepare MOTS-c for patients under physician supervision with a valid prescription. This would not constitute full FDA approval but would enable legal access through the compounding pharmacy system.

Safety Considerations and Current Limitations

Research on MOTS-c safety remains limited, particularly for long-term use in humans. The CB4211 trial demonstrated short-term safety, but four weeks of treatment doesn't reveal potential long-term issues.

Key considerations include:

Dosing uncertainty. The biological activity of MOTS-c is highly dose-dependent, and no optimal dose has been established. Different studies use varying doses, making it difficult to compare results or predict clinical responses.

Delivery challenges. MOTS-c and other mitochondrial peptides have poor bioavailability. Injectable forms may not reach target tissues effectively.

Unknown interactions. How MOTS-c interacts with medications for diabetes, metabolic syndrome, or other conditions hasn't been systematically studied.

Cancer concerns. While some preliminary data suggests MOTS-c may have anti-cancer properties, the effects of sustained AMPK activation and cell proliferation changes need more investigation.

Anyone considering MOTS-c should work with a qualified healthcare provider and understand that this remains an investigational compound without established clinical protocols.

Key Takeaways

• MOTS-c is a 16-amino acid peptide encoded in mitochondrial DNA that activates AMPK and mimics some metabolic benefits of exercise
• Circulating levels decline roughly 21% between young adulthood and old age, correlating with reduced insulin sensitivity and physical capacity
• Animal studies show improved running endurance, insulin sensitivity, and muscle protection with MOTS-c treatment
• Human clinical trials of the analog CB4211 showed safety and modest metabolic improvements, but development was discontinued due to delivery challenges
• The FDA PCAC will review MOTS-c for the 503A compounding bulks list at its July 23-24, 2026 meeting

Frequently Asked Questions

What is MOTS-c and where does it come from?

MOTS-c is a 16-amino acid peptide encoded within mitochondrial DNA, specifically in a previously overlooked region of the 12S rRNA gene. It was discovered in 2015 by Dr. Pinchas Cohen's team at USC. Unlike most proteins that are encoded in nuclear DNA, MOTS-c originates from mitochondria and can signal both within cells and systemically through the bloodstream.

How does MOTS-c work in the body?

MOTS-c activates AMPK (AMP-activated protein kinase), the same pathway triggered by exercise and fasting. This activation increases glucose uptake into cells, promotes fat burning, stimulates production of new mitochondria, and suppresses mTOR signaling. Under stress conditions, MOTS-c also translocates into the cell nucleus, where it regulates gene expression through interaction with the NRF2 transcription factor.

Can MOTS-c replace exercise?

No. While MOTS-c activates similar metabolic pathways as exercise and has been called an "exercise mimetic," it cannot replicate the full benefits of physical activity. Exercise provides cardiovascular conditioning, neuromuscular adaptation, bone strengthening, and psychological benefits that a peptide cannot deliver. MOTS-c may support some of the same metabolic pathways, but it should be viewed as complementary to, not a replacement for, regular physical activity.

Is MOTS-c FDA approved?

MOTS-c is not FDA approved for any indication. It is currently under regulatory review for potential inclusion on the 503A compounding bulks list. The PCAC will discuss MOTS-c at its July 23-24, 2026 meeting. If ultimately added to the 503A list, it could be legally compounded by licensed pharmacies for patients with valid prescriptions, but this is not the same as full FDA drug approval.

Why do MOTS-c levels decline with age?

The exact reasons remain under investigation. Mitochondrial function generally declines with age, which may reduce MOTS-c production. Some research suggests the body attempts to compensate by increasing local MOTS-c expression in skeletal muscle, even as circulating levels fall. The decline correlates with reduced insulin sensitivity and exercise capacity, making it a potential biomarker for metabolic aging.

Sources

• MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis - Nature Communications
• MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation - Frontiers in Endocrinology
• Mitochondrial-encoded peptide MOTS-c prevents pancreatic islet cell senescence to delay diabetes - Experimental & Molecular Medicine
• Mitochondria-derived peptide MOTS-c restores mitochondrial respiration in type 2 diabetic heart - Frontiers in Physiology
• MOTS-c modulates skeletal muscle function by directly binding and activating CK2 - iScience
• Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases - Diabetes & Metabolism Journal
• CohBar Announces Positive Topline Results from the Phase 1a/1b Study of CB4211 - GlobeNewswire
• July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - FDA
• Increased expression of the mitochondrial derived peptide, MOTS-c, in skeletal muscle of healthy aging men - Aging

---

This content is for informational purposes only and is not medical advice. MOTS-c remains an investigational compound without established safety profiles for human use. Consult a healthcare provider before considering any peptide therapy.